Table: Aska Pharmaceutical -2015/16 parent results
May 12 (Reuters)-
Aska Pharmaceutical Co Ltd
PARENT-ONLY FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
Year ended Year ended Year to NEXT
Mar 31, 2016 Mar 31, 2015 Mar 31, 2017 YEAR
LATEST YEAR-AGO COMPANY COMPANY
RESULTS RESULTS FORECAST H1 FORECAST
Sales 39.53 40.52
(-2.4 pct) (+3.1 pct)
Operating 869 mln 1.45
(-39.9 pct) (+142.7 pct)
Recurring 1.23 1.75
(-29.9 pct) (+87.4 pct)
Net 404 mln 1.25
(-67.6 pct) (+177.9 pct)
EPS 14.38 yen 44.46 yen
Ann Div 14.00 yen 14.00 yen 14.00 yen
-Q2 Div 7.00 yen 7.00 yen 7.00 yen
-Q4 Div 7.00 yen 7.00 yen 7.00 yen
NOTE - Aska Pharmaceutical Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4514.T
((Tokyo Headline News Desk +813 6441 1812))
Recent news on ASKA Pharmaceutical Holdings
See all newsTable: Aska Pharmaceutical Holdings -Q1 group results
Brief: Dalton Investment Strongly Oppose Conditional Activation Of Countermeasures Announced By Aska Pharmaceutical Holdings On May 25
Brief: Aska Pharmaceutical -Plan To Put To Shareholders Proposal On Countermeasures Against Potential Large-Scale Share Purchase By Dalton And Related Parties
Table: Aska Pharmaceutical Holdings -2025/26 group results
Table: Aska Pharmaceutical Holdings -2025/26 group results